Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout

International Journal of Rheumatic Diseases

Volumn 14, Issue 3, 2011, Pages

  Tran, Ai P ^a   Edelman, Jack ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

Anakinra; Gout; Inflammasome; Interleukin 1 inhibition; Tophaceous

Indexed keywords

ALLOPURINOL; BENZBROMARONE; C REACTIVE PROTEIN; COLCHICINE; CREATININE; FEBUXOSTAT; FLUCLOXACILLIN; INDOMETACIN; INTERLEUKIN 1; METHYLPREDNISOLONE; PREDNISOLONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CASE REPORT; CHRONIC DISEASE; CHRONIC TOPHACEOUS GOUT; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; EMERGENCY WARD; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; GOUT; HUMAN; HUMAN TISSUE; INTERPHALANGEAL JOINT; KIDNEY DISEASE; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROXIMAL INTERPHALANGEAL JOINT; SMOKING HABIT; TREATMENT DURATION;

ACUTE DISEASE; AGED; ALLOPURINOL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; COLCHICINE; DRUG RESISTANCE; GOUT; GOUT SUPPRESSANTS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79961160191     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01629.x     Document Type: Article

References (14)

1. Roddy E, Zhang W, Doherty M (2007) The changing epidemiology of gout. Nat Clin Pract Rheumatol 3, 443-9.
2. Mikuls T, Saag K (2006) New insights into gout epidemiology. Curr Opin Rheumatol 18, 199-203.
3. Choi H, Mount D, Reginato A (2005) Pathogenesis of gout. Ann Intern Med 143, 499-516.
4. Di Giovine F, Malawista S, Nuki G et al. (1987) Interleukin 1 (IL1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL1. J Immunol 138, 3213-8.
5. Martinon F, Petrilli V, Mayor A et al. (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-41.
6. So A. (2008) Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 10, 221.
7. Hoffman H, Firestein G (2008) IL-1 targeted therapy in autoinflammatory diseases. Int J Adv Rheumatol 6, 74-81.
8. So A, Desmedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9, R28.
9. Terkeltaub R, Sundy J, Schumacher H et al. (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo controlled, mono-sequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 68, 1613-7.
10. McGonagle D, Tan A, Shankaranarayana S et al. (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 66, 1683-4.
11. Chen K, Fields T, Mancuso C et al. (2010) Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 40, 210-4.
12. Gratton S, Scalapino K, Fye K (2009) Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum 61, 1268-70.
13. The Commonwealth Department of Health and Aging (2009) National Hospital Cost Data Collection. Cost report round 12 (2007-2008). Commonwealth of Australia, Canberra, Australia. [Cited 14 Oct 2009.] Available from URL: .
14. Hoffman H, Throne M, Amar N et al. (2008) Efficacy and safety of rilonacept (Interleukin-1 Trap) in patients with Cryopyrin Associated Periodic Syndromes. Arth Rheum 58, 2443-52.